facebook button AdvanTIG-205: Ociperlimab and Tislelizumab as First-Line Treatment
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

AdvanTIG-205: Ociperlimab and Tislelizumab as First-Line Treatment in the Metastatic Setting

Sponsor: BeiGene, Ltd.

AdvanTIG-205: A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations who have Received No Previous Treatment for Metastatic Disease

Ociperlimab and Tislelizumab in the first line setting for patients with stage IV squamous or non-squamous non-small cell lung cancer.

For more information please contact the research department at 631-675-5075.